Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07361406

SweetSpot - The Effect of Non-nutritive Sweeteners on Health

The aim of the study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

45 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Wageningen University & Research

Wageningen, Gelderland, 6708WG, Netherlands

Location status: Recruiting

Location contact

Diederik Esser, Dr.

CONTACT

[email protected]

+31317480084

About this study

Sugar intake has increased over the years, simultaneously with the prevalence of overweight and obesity. To decrease sugar intake, consumption of non-nutritive sweeteners (NNS) has increased and opinions on its use remain divided. A fully controlled dietary intervention using a NNS mixture and dose that is similar to real-life intake, is therefore necessary to advance our understanding of the potential effects of NNS on glucose regulation, gut microbiome, and gut hormone secretion under real-life conditions.

The aim of this study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.

To do this, a single blind, fully controlled dietary intervention with a cross-over design will be performed. The study will consist of 2x8 weeks of intervention, with a washout of > 6 weeks in between. The study population will be 60 healthy adults aged 45-79, with a BMI between 20-35 kg/m2.

The study will consist of a fully controlled diet of two 8-week intervention periods (2 weeks run-in + 6 weeks intervention). The diets differ in the presence of non-nutritive sweeteners (NNS): NNS-diet versus non-NNS diet, where additional NNS are added to the NNS-diet.

The primary outcome measure will be the within person difference in blood glucose incremental area under the curve following a 75 g glucose tolerance test between the NNS diet and the non-NNS diet. Secondary outcome measures are the effect of NNS on Matsuda index, insulin response, blood lipid profile, and gut hormone secretion will be determined. The effect of NNS on small- and large intestinal microbiome will be investigated by a change in composition, functionality, and short chain fatty acid content. The effect of NNS on sweet taste sensitivity, preference, and liking will be investigated, as well as the excretion of NNS in urine and saliva.

The total time invested by participants is around 85 hours. Participants are restricted for 16 weeks in their eating habits, since they follow a fully controlled diet prepared by the research facility. Participants will visit the research facility in total 38 times. In total, ~ 603 mL of blood will be drawn by experienced nurses over the entire RCT (>6 month period). During DEXA scans, participants will receive a total of about 0.006 mSv of radiation.

Invasive measurements that participants can experience as burden are collection of faecal and urine samples, and finding back the Simba capsules in the stool. Non-invasive measurements for participants are wearing the CGM, wearing the ActiGraph, consuming the blue cakes, and performing sensory tests.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 45-79 years;
  • BMI of 20-35 kg/m2;
  • Having veins suitable for placement of a venflon catheter.

Exclusion criteria

  • Diseases or prior surgeries affecting the stomach, liver, kidneys or intestines (allowed i.e. appendectomy);
  • Cardiovascular diseases (e.g. heart failure) or cancer (e.g. non-invasive skin cancer allowed);
  • Diagnosed with type 1 or type 2 diabetes;
  • Drug treated thyroid diseases (well substituted hypothyroidism is allowed for inclusion);
  • HbA1c level >6.5% (>48 mmol/mol), as measured during the screening visit;
  • Anaemia defined as Hb concentrations <8.5 mmol/L for men and <7.5 mmol/L for women via finger prick;
  • Regular use of/receiving medication interfering with research outcomes (as judged by research physician), such as use of glucose lowering drugs, insulin, or use of medication that impacts the gastro-intestinal system;
  • Use of antibiotics over the last 3 months before study start;
  • Donated blood within 2 months prior to the screening;
  • Food allergies, intolerances (including lactose/gluten intolerance) for products used in the study design and/or dietary restrictions interfering with the study (including special diets and eating disorders);
  • Followed a diet that can interfere with the study outcomes within 1 month prior to the screening (e.g. ketogenic, sugar free, carbohydrate free);
  • Not willing to eat all products in the study diet, including eggs and dairy. Vegetarian is possible;
  • Not willing to consume non-nutritive sweeteners;
  • Not willing to quit the use of supplements that can interfere with the study outcomes (e.g. pre- or probiotics).
  • Intention to change the intensity of exercise during the study period or planning to join a intensive sport event (e.g. marathon or triathlon);
  • Intention to lose or gain weight;
  • Working night shifts regularly;
  • Smoking regularly
  • Use of soft and/or hard drugs (cannabis included);
  • Abuse of alcohol (defined as >14 glasses (women) or >21 glasses (men) of alcoholic beverages per week);
  • Being pregnant or lactating or planning to become pregnant;
  • Inability to understand study information and/or communicate with staff;
  • Participation in another study that involves an intervention within two months prior to the intervention;
  • Working or doing a thesis/internship at the division of Human Nutrition & Health, or the Food, Health & Consumer Research group of Wageningen Food & Biobased Research.

Treatment and study plan

Diet with non-nutritive sweeteners

Other

Fully controlled diet with added mixture of non-nutritive sweeteners. The mixture consist of 6 different non-nutritive sweeteners: acesulfame-K, aspartame, cyclamate, saccharin, sucralose, and rebaudioside A (stevia).

Diet without non-nutritive sweeteners

Other

Fully controlled diet without any non-nutritive sweeteners added.

Primary outcomes

  1. Difference in change in 2h iAUC glucose after 6 weeks between the intervention and the control.

    Time frame: Week 2 and week 8 in both intervention periods (4 times in total)

    The primary outcome measure is the difference in change in iAUC of blood glucose levels following a 2-hour oral glucose tolerance test (OGTT) after six weeks between the intervention period and the control period.

Secondary outcomes

  1. Matsuda index

    Time frame: Week 2 and week 8 in both intervention periods (4 times in total)

    Matsuda index after an OGTT

  2. Fasting blood glucose

    Time frame: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

    Fasting blood glucose

  3. Fasting blood insulin

    Time frame: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

    Fasting blood insulin

  4. Postprandial insulin response

    Time frame: Week 2 and 8 in both intervention periods (4 times in total).

    2-hour iAUC blood insulin during OGTT

  5. Postprandial glucose response after a breakfast

    Time frame: Week 7 in both study periods (2 times in total)

    Postprandial blood glucose responses (PPGR) following specific meals measured by CGM.

  6. Blood lipid profile

    Time frame: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

    All circulating blood lipids, including all cholesterol types, triglycerides, and free fatty acids (FFAs).

  7. Gut microbiota composition

    Time frame: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.

    Microbiota composition in faeces

  8. Gut microbiota function

    Time frame: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.

    Microbiota functionality measured in faeces

  9. Microbial metabolites

    Time frame: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.

    Microbial metabolites measured in faeces

  10. Small intestinal microbiota composition

    Time frame: Week 7 of both intervention periods (2 times in total).

    Microbiota composition of the small intestine measured with Simba Capsules

  11. Gastro-intestinal transit time

    Time frame: Baseline & week 7 of both intervention periods (3 times in total).

    Gastro-intestinal transit time measured with blue muffins.

  12. Oral microbiome composition & function

    Time frame: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

    Oral microbiome composition & function measured in saliva

  13. Postprandial GLP-1 secretion

    Time frame: Week 2 and 8 of both intervention periods (4 times in total).

    3-hour AUC of GLP-1 during an OGTT.

  14. Postprandial GIP secretion

    Time frame: Week 2 and 8 of both intervention periods (4 times in total).

    3-hour AUC of GIP during an OGTT.

  15. Sweetness-liker phenotype

    Time frame: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

    Sweetness-liker phenotype, with the sweetness liker test.

  16. Sweetness preference & liking

    Time frame: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

    Sweetness preference & liking measured on a rank-rating scale. Preference will be determined using the categorical values from the rank-rating scale (1-5), and liking will be determined using the continuous values from the rank-rating scale (0-100).

  17. Sweet taste sensitivity

    Time frame: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

    Sweet taste sensitivity measured on a 100mm Visual Analogue Scale. A higher score for all solutions indicates a higher sweet taste sensitivity.

  18. Excretion of NNS in urine

    Time frame: Baseline, week 2 and week 8 in intervention period 1, and every two weeks in intervention period 2 (7 times in total).

    Excretion of NNS in urine

  19. Excretion of NNS in saliva

    Time frame: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

    Excretion of NNS in saliva

Other outcomes

  1. Anthropometrics

    Time frame: Baseline

    Measured as weight (kg), height (m), waist circumference (cm), and hip circumference (cm). Weight and height will be combined to report BMI in kg/m^2.

  2. Body composition

    Time frame: Baseline & week 8 of both intervention periods (3 times in total).

    Body composition as measured by DEXA (Dual Energy X-ray Absorptiometry).

  3. Habitual food intake

    Time frame: Baseline

    Habitual dietary intake assessment with a food frequency questionnaire (FFQ).

  4. Physical activity level

    Time frame: Baseline.

    Physical activity level by the Short Questionnaire to Assess Health-enhancing physical activity (SQUASH).

  5. Habitual NNS consumption

    Time frame: Baseline

    Habitual NNS consumption by questionnaire

  6. Gastro-intestinal symptoms

    Time frame: Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.

    Gastro-intestinal symptoms by GSRS questionnaire.

  7. Satiety

    Time frame: Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.

    Satiety questionnaire, adapted from the Control of Eating Questionnaire.

  8. Genetic variation

    Time frame: Baseline

    Single Nucleotide Polymorphisms (SNPs) in genes relevant collected using buffycoat.

  9. Taste function

    Time frame: Baseline

    Measure the ability to recognize the basic tastes in different concentrations, assessed with validated Taste Strips.

Sponsors and collaborators

Lead sponsor

Wageningen University

Other

Collaborators

  • American Beverage Association
  • Food & Biobased Research - Wageningen UR
  • Symrise AG
  • TKI Agri & Food
  • Tate & Lyle
  • The Magnum Ice Cream Company
  • Yildiz Holding

Registry information

Official study title

SweetSpot - The Effect of Non-nutritive Sweeteners on Glucose Regulation, Gut Microbiome, and Gut Hormone Secretion in Healthy Adults: a Fully Controlled Cross-over Intervention Study

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 23, 2026
Registry last updated
Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.